Ultragenyx Pharmaceutical Inc. (FRA:UP0)

Ultragenyx Pharmaceutical Statistics

Total Valuation

FRA:UP0 has a market cap or net worth of EUR 2.76 billion. The enterprise value is 3.13 billion.

Market Cap	2.76B
Enterprise Value	3.13B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	96.30M
Shares Outstanding	n/a
Shares Change (YoY)	+12.26%
Shares Change (QoQ)	+1.33%
Owned by Insiders (%)	3.50%
Owned by Institutions (%)	101.66%
Float	92.89M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.14
PB Ratio	200.72
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.33
EV / Sales	5.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.13

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 53.41.

Current Ratio	1.89
Quick Ratio	1.59
Debt / Equity	53.41
Debt / EBITDA	n/a
Debt / FCF	-1.91
Interest Coverage	-9.37

Financial Efficiency

Return on equity (ROE) is -313.43% and return on invested capital (ROIC) is -31.69%.

Return on Equity (ROE)	-313.43%
Return on Assets (ROA)	-24.92%
Return on Invested Capital (ROIC)	-31.69%
Return on Capital Employed (ROCE)	-63.97%
Revenue Per Employee	415,347
Profits Per Employee	-381,907
Employee Count	1,294
Asset Turnover	0.46
Inventory Turnover	16.63

Taxes

In the past 12 months, FRA:UP0 has paid 2.65 million in taxes.

Income Tax	2.65M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-33.78%
50-Day Moving Average	27.35
200-Day Moving Average	29.66
Relative Strength Index (RSI)	58.03
Average Volume (20 Days)	28

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.24

Income Statement

In the last 12 months, FRA:UP0 had revenue of EUR 537.46 million and -494.19 million in losses. Loss per share was -5.06.

Revenue	537.46M
Gross Profit	-139.62M
Operating Income	-463.65M
Pretax Income	-491.54M
Net Income	-494.19M
EBITDA	-433.57M
EBIT	-463.65M
Loss Per Share	-5.06

Balance Sheet

The company has 362.44 million in cash and 735.63 million in debt, giving a net cash position of -354.38 million.

Cash & Cash Equivalents	362.44M
Total Debt	735.63M
Net Cash	-354.38M
Net Cash Per Share	n/a
Equity (Book Value)	13.77M
Book Value Per Share	0.08
Working Capital	258.40M

Cash Flow

In the last 12 months, operating cash flow was -379.85 million and capital expenditures -4.87 million, giving a free cash flow of -384.72 million.

Operating Cash Flow	-379.85M
Capital Expenditures	-4.87M
Free Cash Flow	-384.72M
FCF Per Share	n/a

Margins

Gross margin is -25.98%, with operating and profit margins of -86.27% and -91.95%.

Gross Margin	-25.98%
Operating Margin	-86.27%
Pretax Margin	-91.46%
Profit Margin	-91.95%
EBITDA Margin	-80.67%
EBIT Margin	-86.27%
FCF Margin	n/a

Dividends & Yields

FRA:UP0 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.26%
Shareholder Yield	-12.26%
Earnings Yield	-17.88%
FCF Yield	-13.92%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:UP0 has an Altman Z-Score of -3.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.98
Piotroski F-Score	4